Neola Medical

Bifogade filer

Neola Medical’s CEO shares recent company highlights in winter 2025 investor letter

Neola Medical Investor Letter Winter 2025

Kurs

+2,71%

Likviditet

0,01 MSEK

Prenumeration

Kalender

	Est. tid*
2026-05-19	19:00	Kvartalsrapport 2026-Q1
2026-02-12	07:50	Bokslutskommuniké 2025
2025-11-05	-	Kvartalsrapport 2025-Q3
2025-08-22	-	Kvartalsrapport 2025-Q2
2025-05-22	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2025-05-21	-	Årsstämma
2025-05-21	-	Kvartalsrapport 2025-Q1
2025-02-12	-	Bokslutskommuniké 2024
2024-11-06	-	Kvartalsrapport 2024-Q3
2024-08-15	-	Kvartalsrapport 2024-Q2
2024-05-23	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2024-05-22	-	Årsstämma
2024-05-22	-	Kvartalsrapport 2024-Q1
2024-02-14	-	Bokslutskommuniké 2023
2023-12-29	-	Extra Bolagsstämma 2023
2023-11-09	-	Kvartalsrapport 2023-Q3
2023-08-15	-	Kvartalsrapport 2023-Q2
2023-05-19	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2023-05-17	-	Årsstämma
2023-05-17	-	Kvartalsrapport 2023-Q1
2023-02-14	-	Bokslutskommuniké 2022
2022-11-10	-	Kvartalsrapport 2022-Q3
2022-09-27	-	Extra Bolagsstämma 2022
2022-08-16	-	Kvartalsrapport 2022-Q2
2022-05-20	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2022-05-19	-	Årsstämma
2022-05-19	-	Kvartalsrapport 2022-Q1
2022-02-15	-	Bokslutskommuniké 2021
2021-11-09	-	Kvartalsrapport 2021-Q3
2021-09-14	-	Extra Bolagsstämma 2021
2021-08-17	-	Kvartalsrapport 2021-Q2
2021-05-21	-	X-dag ordinarie utdelning NEOLA 0.00 SEK
2021-05-20	-	Årsstämma
2021-05-20	-	Kvartalsrapport 2021-Q1
2021-02-16	-	Bokslutskommuniké 2020
2020-11-11	-	Kvartalsrapport 2020-Q3

Beskrivning

Land	Sverige
Lista	First North Stockholm
Sektor	Hälsovård
Industri	Medicinteknik

Neola Medical är verksamt inom medicinteknik. Bolaget är inriktade mot neonatalvården där de utvecklar medicinteknisk utrustning. Exempel på produkter som bolaget tillhandahåller till sjukvården inkluderar teknisk övervakning och uppföljning av lungkapaciteten hos tidigt födda spädbarn. Utöver huvudprodukten erbjuds kringprodukter och engångsartiklar. Störst verksamhet återfinns inom den nordiska marknaden. Neola Medical grundades 2016 och har huvudkontor i Sverige.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Neola Medical’s CEO shares recent company highlights in winter 2025 investor letter

2025-12-17 11:40:00

As 2025 draws to a close, Neola Medical reflects on a year shaped by meaningful clinical progress and continued organizational strengthening. During the winter, the company further reinforced its technological and intellectual property foundation, supporting long-term development. Preparations for clinical progression also continued through site visits at leading neonatal intensive care units in the U.S.

“2025 has been a year of important clinical and organizational progress for Neola Medical. With a solid technological and intellectual property foundation, we continue to move forward in both our clinical development and organizational growth,” says CEO Hanna Sjöström.

Read more in the investor letter winter 2025, attached to this press release and available on the company’s website www.neolamedical.com

About Neola Medical
Neola Medical AB (publ) develops an innovative medical technology device for non-invasive, continuous lung monitoring and real-time alerts of potentially life-threatening lung complications in preterm born babies. By enabling instant detection, the technology aims to support earlier intervention, improve clinical decision-making, enhance long-term outcomes, and ultimately contribute to saving lives. The patented, cutting-edge technology was developed at Lund University in Sweden and is based on a spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola Medical builds on Sweden’s longstanding legacy of medical technology innovation and contributions to global health care. Neola Medical was founded in 2016 and is listed on NASDAQ First North Growth Market (ticker: NEOLA). Read more at www.neolamedical.com. The company’s Certified Adviser is FNCA Sweden AB.

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Neola Medical

Bifogade filer

Kurs +2,71%

Likviditet 0,01 MSEK